| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32d3183d4bb6f11844fba6230e4a3bc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2c58c0a1227cc8b33ae139d0223c14b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab1b091a5f6b1ea6c2ce530ce9644642 |
| publicationDate |
2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020038363-A1 |
| titleOfInvention |
Composition for preventing or treating neurological and mental disorders, containing syringaresinol |
| abstract |
The present invention relates to a pharmaceutical composition for prevention or treatment of neurological diseases and mental diseases, the composition containing syringaresinol. The syringaresinol according to the present invention has an effect of reducing excitatory synaptic transmission in a central nervous system and an effect of suppressing epilepsy and activity of animals. This suppressive effect of the excitatory synaptic transmission may be effectively used for the prevention and treatment of all neurological diseases and mental diseases resulting from synapse dysfunction and synpatic excitatory-inhibitory transmission imbalance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10853769-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11616856-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11514021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10867285-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11080105-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11080734-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11501351-B2 |
| priorityDate |
2016-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |